mafosfamide has been researched along with Chromosomal Translocation in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellosillo, B; Bosch, F; Campo, E; Colomer, D; Espinet, B; Ferrer, A; López-Guillermo, A; Marcé, S; Montserrat, E; Solé, F; Villamor, N | 1 |
| Hegewisch-Becker, S; Hossfeld, DK; Krüger, W; Peters, SO; Stockschläder, M; Weh, HJ; Zander, AR | 1 |
| Chelstrom, LM; Gunther, R; Jansen, B; Jaszcz, WB; Kersey, JH; Nguyen, DP; Tuel-Ahlgren, L; Uckun, FM | 1 |
3 other study(ies) available for mafosfamide and Chromosomal Translocation
| Article | Year |
|---|---|
Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Coloring Agents; Cyclophosphamide; DNA Damage; Enzyme Inhibitors; Flow Cytometry; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Membrane Potentials; Mitochondria; Mitoxantrone; Proteins; Reactive Oxygen Species; Staurosporine; Time Factors; Translocation, Genetic; Tumor Suppressor Protein p53; Vidarabine | 2004 |
Infusion of tumor-contaminated bone marrow for autologous rescue after high-dose therapy leading to long-term remission in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Bone Marrow Purging; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Translocation, Genetic | 1995 |
Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Topics: Acute Disease; Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antigens, CD; Antigens, CD19; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents, Phytogenic; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Cyclophosphamide; Female; Humans; Immunotoxins; Leukemia, Biphenotypic, Acute; Leukemic Infiltration; Male; Mice; Mice, SCID; Molecular Sequence Data; N-Glycosyl Hydrolases; Oligonucleotide Probes; Plant Proteins; Polymerase Chain Reaction; Ribosome Inactivating Proteins, Type 1; Specific Pathogen-Free Organisms; Translocation, Genetic | 1993 |